Micafungin

Echinocandin Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Micafungin is a drug in the Echinocandin Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2005. DrugCentral lists 3 molecular targets, including ABCG2, GSC1 and GSC1. Recorded indications include Candida Peritonitis, Candidal septicemia, Candidemia and Candidiasis of the esophagus.

• Drug class: Echinocandin Antifungal.
• Molecular targets: ABCG2, GSC1 and GSC1 (3 listed in DrugCentral).
• Indications: Candida Peritonitis, Candidal septicemia, Candidemia, Candidiasis of the esophagus and Disseminated candidiasis and others.
• ATC code: J02AX05 (Other antimycotics for systemic use).
• Molecular formula: C56H71N9O23S; molecular weight 1270.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Candida Peritonitis
• Candidal septicemia
• Candidemia
• Candidiasis of the esophagus
• Disseminated candidiasis
• Prevention of Disseminated Candidiasis

Off-label uses (1)

• Oropharyngeal Candidiasis

Contraindications (3)

• Intravascular hemolysis
• Kidney disease
• Liver function tests abnormal

Mechanism & targets

• Established pharmacologic class: Echinocandin Antifungal

Molecular targets (3)

Target	Gene	Action	Activity
ATP-binding cassette sub-family G member 2	ABCG2	unknown	IC50 4.68
Beta-1,3-glucan synthase	GSC1	unknown	—
Beta-1,3-glucan synthase catalytic subunit 1	GSC1	inhibitor	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2008-04-25	EMA	—	Astellas Pharma Europe B.V.
2005-03-16	FDA	—	FUJISAWA HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
J02AX05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	692.1
Aplastic anaemia	607.5
Multiple organ dysfunction syndrome	443.5
Bronchopulmonary aspergillosis	330.1
Aspergillus infection	302.8
Fungal infection	290.6
Cytomegalovirus viraemia	289.7
Acute graft versus host disease in skin	267.0
Drug ineffective	256.6
Pre-engraftment immune reaction	253.6
Lymphoid tissue hypoplasia	242.6
Acute graft versus host disease	241.0

Chemical structure

• Molecular formula: C₅₆H₇₁N₉O₂₃S
• Molecular weight: 1270.29 g/mol
• CAS number: —
• InChIKey: PIEUQSKUWLMALL-LXWXBMNESA-N
• PubChem CID: 477468

CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Micafungin used for?

DrugCentral lists the following indications for Micafungin: Candida Peritonitis, Candidal septicemia, Candidemia, Candidiasis of the esophagus, Disseminated candidiasis and Prevention of Disseminated Candidiasis.

How does Micafungin work?

Its molecular targets in DrugCentral include ABCG2, GSC1 and GSC1 (inhibitor).

When was Micafungin first approved?

Micafungin was first approved by the FDA in 2005.

What drug class does Micafungin belong to?

Micafungin is in the Echinocandin Antifungal class.

What is the chemical formula of Micafungin?

Micafungin has the molecular formula C56H71N9O23S and a molecular weight of 1270.29 g/mol.

Sources

• DrugCentral drug card 1798 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1237070 — compound record and bioactivity
• PubChem CID 477468 — chemical identifiers
• DrugBank DB01141 — drug record
• FDA UNII R10H71BSWG — substance identity
• DailyMed: FDA labels for Micafungin — current prescribing information (label search)
• UniProt Q9UNQ0 (ABCG2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.